Ideal Cures has expanded its drug delivery tech portfolio with a new alginic acid-based, delayed-release coating that – it claims – has advantages over shellac and starch.
Abbott Laboratories will pump €85m ($113m) into the expansion of its API production plant in Sligo, Ireland, in preparation of the launch of its pipeline products.
Shanghai Pharmaceuticals has bought a 70 per cent stake in ingredients developer and manufacturer Changzhou Kony Pharm in a bid to boost its standing in the API market.
DSM Pharmaceutical Products (DPP) will sell APIs made by Indian manufacturer Indoco Remedies in a new agreement that fits with its global expansion plan.
Swiss API maker Carbogen Amcis has bought French contract manufacturer Creapharm Parenterals to boost capabilities in early-phase high potency drug development.
It’s been a busy year for API (active pharmaceutical ingredient) manufacturers with new facilities, cost pressures and regulatory developments all hitting the headlines.And it seems recent developments in HPAPIs (high potency APIs) have caused a stir...
BASF has raised its prices for three ethanolamines (EOA), key intermediates in the production of a wide range of active pharmaceutical ingredients (API).
Carbogen Amcis has signed a strategic deal with formulations specialist Polymun Scientific in a agreement designed to support the development of its high potency manufacturing business.
Granules India says higher demand for APIs and pharmaceutical intermediates combined with manufacturing productivity gains helped drive quarterly growth.
Solvias and RohnerChem have set up a research and manufacturing services partnership designed to accelerate the production, scale-up and commercialisation of APIs.
Researchers have called for closer monitoring of pharma manufacturing discharges after detecting endocrine disruption in fish downstream from a Sanofi plant.
DMV-Fonterra excipients (DFE) will buy Indian manufacturer Brahmar Cellulose Private Limited (BCPL) to strengthen its position in the pharmaceutical excipient market and reduce costs.
Contract manufacturing organisation (CMO) Neuland Laboratories will showcase its expanded capabilities for synthetic peptide manufacture at the 22nd American Peptide Symposium to be held in San Diego, US later this week.
Ubichem Fine Chemicals has sold a majority stake in Ubichem Research, which provides chemistry services to drug developers through its Ubichem Pharma Services, to investment group Lochlomond Holding.
PolyPid claims its new polymer-lipid combination delivery tech will let pharmas set precise release characteristics for a variety of small molecule, protein and nucleic acid-base drugs.
Chinese (API) maker ScinoPharm said that it met its sales targets in 2010, despite rocketing raw materials prices, cutbacks in government healthcare spending in key markets and currency revaluation.
Swiss pharmaceutical ingredient maker Helsinn says its new cytotoxic API production plant will be operational for laboratory-scale projects early next year.
CSM GlobalPharma has announced plans to invest $65m in a manufacturing facility in Kigali, Rwanda in collaboration with the Rwandan Development Board (RDB).
ShangPharma has opened a multi-purpose pharmaceutical development cGMP manufacturing facility in Fengxian, China, and started operations on the initial phase of production.
ShangPharma has raised $87m through an IPO on the New York Stock Exchange according to a Bloomberg report, beating the $46m to $53m the Chinese CRO forecast.
Almac invests $4m in biocatalysis R&D, describing such technologies as the way forward for the cost efficient production of highly chiral APIs and intermediates.
Indian API manufacturer Shasun Chemicals and Drugs turned a previous loss into profit for Q4 of this year as it seeks to make a dent in the biosimilar manufacturing sector.
The Office of the United States Trade Representative (USTR) has expressed particular concern about the proliferation of counterfeit drugs in countries including Brazil, China, India, Indonesia and Russia.
